[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333938-105":59,"doc-detail-333938-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","novel-cd44-targeted-albumin-nanoparticles-an-innovative-approach-to-improve-breast-cancer-treatment","Novel CD44-Targeted Albumin Nanoparticles - An Innovative Approach to Improve Breast Cancer Treatment","","This study introduces novel CD44-targeted and redox-responsive nanoparticles (FNPs) as doxorubicin (DOX) delivery devices for breast cancer. A cationized, redox-responsive Human Serum Albumin derivative is synthesized by conjugating Human Serum Albumin with cystamine moieties, then ionically complexing it with HA. Physicochemical characterization includes size distribution, morphology, and zeta potential (15.4 mV), while assays evaluate DOX loading efficiency (90%) and redox-triggered release (55% after 2 h).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-cd44-targeted-albumin-nanoparticles-an-innovative-approach-to-improve-breast-cancer-treatment/333938/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-cd44-targeted-albumin-nanoparticles-an-innovative-approach-to-improve-breast-cancer-treatment/333938.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapeutic role do CD44-targeted redox-responsive nanoparticles play in this study?","Question",{"text":113,"@type":114},"They are proposed as doxorubicin delivery devices designed to improve breast cancer treatment by targeting the CD44 protein and responding to redox conditions in the tumor environment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are the nanoparticles prepared and what key characterization parameters are used?",{"text":118,"@type":114},"A cationized, redox-responsive Human Serum Albumin derivative is synthesized via conjugation with cystamine moieties and ionically complexed with hyaluronic acid. Suitability is assessed through physicochemical measurements including size distribution, morphology, and zeta potential (15.4 mV).",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence indicates enhanced drug release and antitumor activity?",{"text":122,"@type":114},"The formulation shows high DOX loading efficiency (90%) and redox-triggered release with 55% release after 2 h incubation. The carrier increases DOX cytotoxicity relative to free DOX, associated with reduced metabolism, altered oxidative phosphorylation-related proteins, and decreased viability, motility, breast cancer stem cells, and spheroid formation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},333938,1790077413,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Article  \nNovel CD44-Targeted Albumin Nanoparticles: An Innovative Approach to Improve Breast Cancer Treatment  \nGiuseppe Cirillo †, Anna Rita Cappello†, Manuela Curcio *, Marco Fiorillo *, Luca Frattaruolo , Paola Avena, Ludovica Scorzafave, Vincenza Dolce , Fiore Pasquale Nicoletta  and Francesca Iemma   \nCitation: Cirillo, G.; Cappello, A.R.; Curcio, M.; Fiorillo, M.; Frattaruolo, L.; Avena, P.; Scorzafave, L.; Dolce, V.; Nicoletta, F.P.; Iemma, F. Novel CD44-Targeted Albumin Nanoparticles: An Innovative Approach to Improve Breast Cancer Treatment. Int. J. Mol. Sci. 2024, 25, 10560. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms251910560  \nAcademic Editor: Hélder A. Santos  \nReceived: 2 September 2024  \nRevised: 23 September 2024  \nAccepted: 25 September 2024  \nPublished: 30 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende (CS), Italy; [giuseppe.cirillo@unical.it](giuseppe.cirillo@unical.it) (G.C.); annarita.cappello@unical.it (A.R.C.); [luca.frattaruolo@unical.it](luca.frattaruolo@unical.it) (L.F.);  \n[paola.avena@unical.it](paola.avena@unical.it) (P.A.); [ludovicascorzafave@gmail.com](ludovicascorzafave@gmail.com) (L.S.); [vincenza.dolce@unical.it](vincenza.dolce@unical.it) (V.D.);  \nfiore.nicoletta@unical.it (F.P.N.); francesca.iemma@unical.it (F.I.)  \n* [Correspondence: manuela.curcio@unical.it](Correspondence: manuela.curcio@unical.it) (M.C.); [marco.fiorillo@unical.it](marco.fiorillo@unical.it) (M.F.)† These authors contributed equally to this work.  \nAbstract: This study introduces novel CD44-targeted and redox-responsive nanoparticles (FNPs), proposed as doxorubicin (DOX) delivery devices for breast cancer. A cationized and redox-responsive Human Serum Albumin derivative was synthesized by conjugating Human Serum Albumin with cystamine moieties and then ionically complexing it with HA. The suitability of FNPs for cancer therapy was assessed through physicochemical measurements of size distribution (mean diameter of 240 nm), shape, and zeta potential (15.4 mV). Nanoparticles possessed high DOX loading efficiency (90%) and were able to trigger the drug release under redox conditions of the tumor environment (55% release after 2 h incubation) . The use of the carrier increased the cytotoxic effect of DOX by targeting the CD44 protein. It was shown that, upon loading, the cytotoxic effect of DOX was enhanced in relation to CD44 protein expression in both 2D and 3D models. DOX@FNPs significantly decrease cellular metabolism by reducing both oxygen consumption and extracellular acidification rates. Moreover, they decrease the expression of proteins involved in the oxidative phosphorylation pathway, consequently reducing cellular viability and motility, as well as breast cancer stem cells and spheroid formation, compared to free DOX. This new formulation could become pioneering in reducing chemoresistance phenomena and increasing the specificity of DOX in breast cancer patients.  \nKeywords: breast cancer; ionic nanoparticles; hyaluronic acid; cationized albumin; vectorization  \n1. Introduction  \nCancer, a major problem in the 21st century, is among the three leading causes of death in patients aged between 30 and 69 years worldwide [1] . It impacts society from societal, public health, and economic points of view, varying in degree across cancer types, geography, and gender [2] . According to the latest GLOBOCAN estimates produced by the International Agency for Research on Cancer, female breast cancer is the second leading cause of global cancer incidence in 2022, comprisi","cbCainlYTs3HfoLG","https://ap.wps.com/l/cbCainlYTs3HfoLG","pdf",3140164,16,"English","# Introduction\n## Targeted nanotechnology in cancer therapy\n## Limitations of passive targeting and multidrug resistance\n# Materials and Methods\n## Nanoparticle synthesis and formulation\n# Results\n## Physicochemical characterization\n## DOX loading and redox-triggered release\n## Antitumor effects in 2D/3D models","[{\"question\":\"What therapeutic role do CD44-targeted redox-responsive nanoparticles play in this study?\",\"answer\":\"They are proposed as doxorubicin delivery devices designed to improve breast cancer treatment by targeting the CD44 protein and responding to redox conditions in the tumor environment.\"},{\"question\":\"How are the nanoparticles prepared and what key characterization parameters are used?\",\"answer\":\"A cationized, redox-responsive Human Serum Albumin derivative is synthesized via conjugation with cystamine moieties and ionically complexed with hyaluronic acid. Suitability is assessed through physicochemical measurements including size distribution, morphology, and zeta potential (15.4 mV).\"},{\"question\":\"What evidence indicates enhanced drug release and antitumor activity?\",\"answer\":\"The formulation shows high DOX loading efficiency (90%) and redox-triggered release with 55% release after 2 h incubation. The carrier increases DOX cytotoxicity relative to free DOX, associated with reduced metabolism, altered oxidative phosphorylation-related proteins, and decreased viability, motility, breast cancer stem cells, and spheroid formation.\"}]","Novel CD44-Targeted Albumin Nanoparticles - An Innovative Approach to Improve Breast Cancer Treatment | PDF",1790004697]